Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹184 Cr
Revenue (TTM)
₹113 Cr
Net Profit (TTM)
₹-18 Cr
ROE
0 %
ROCE
-25.6 %
P/E Ratio
--
P/B Ratio
-4.5
Industry P/E
44.74
EV/EBITDA
-15
Div. Yield
0 %
Debt to Equity
-2.5
Book Value
₹-11.1
EPS
₹-4.8
Face value
10
Shares outstanding
36,983,500
CFO
₹-23.12 Cr
EBITDA
₹-44.15 Cr
Net Profit
₹-47.29 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oxygenta Pharma
| -10.8 | -6.8 | -7.2 | -36.9 | 10.8 | -- | 16.3 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Oxygenta Pharma
| -34.9 | 173.3 | 9.9 | 2.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oxygenta Pharma
|
49.8 | 184.0 | 112.8 | -18.0 | -17.3 | -- | -- | -4.5 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
S.S. Organics Limited manufactures and sells anti ulcerative and anti-bacterial drugs in India. It is also involved in contract manufacturing work, including cirprofloxacin HCL from Q-acid and cloxacillim sodium. The company was incorporated in 1990... and is based in Hyderabad, India. Read more
Incorporated
1990
Chairman
--
Managing Director
--
Headquarters
Sangareddy, Telangana
Website
Looking for more details about Oxygenta Pharmaceutical Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Oxygenta Pharmaceutical Ltd is ₹49.76 (BSE) as of 02-Apr-2026 IST. Oxygenta Pharmaceutical Ltd has given a return of 10.78% in the last 3 years.
Since, TTM earnings of Oxygenta Pharmaceutical Ltd is negative, P/E ratio is not available.
The P/B ratio of Oxygenta Pharmaceutical Ltd is -4.50 times as on 02-Apr-2026, a 245 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-11.76
|
|
2024
|
0.00
|
-4.69
|
|
2023
|
0.00
|
-1.13
|
|
2022
|
0.00
|
-0.99
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Oxygenta Pharmaceutical Ltd are Rs 133.50 and Rs 45.30 as of 05-Apr-2026.
Oxygenta Pharmaceutical Ltd has a market capitalisation of ₹ 184 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Oxygenta Pharmaceutical Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.77
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.